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under the Community Drugs Scheme. Of these, 2 treatments were reimbursed after a price 
reduction, 2 were borderline, and 1 treatment was cost-effective under the General Medical 
Services scheme but not the Drugs Payment Scheme. Of the 11 products reimbursed by 
NCPE, 5 were recommended by NICE (45%), 6 by SMC (55%) and 1 by AWMSG (9%). 
Not all of the 11 treatments were reviewed by NICE, SMC and/or AWMSG. Furthermore, 
2 of the 11 treatments have been withdrawn in Scotland, England and Wales. Limited 
clinical/economic data was the reason for the one non-recommendation by the SMC. a 
more detailed analysis will be presented. CONCLUSIONS: Although requirements for 
HTA submissions vary between countries, demonstrating cost-effectiveness is a key factor 
for reimbursement in all markets investigated.
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OBJECTIVES: The Inpatient Psychiatric Facility Prospective Payment System (IPF 
PPS) is the youngest of the Medicare PPSs. Inpatient Psychiatric Facilities (IPFs) were 
excluded from the acute care inpatient diagnosis-related groups (DRG) system as it 
was thought to be a poor predictor of resource use for psychiatric patients. Although 
the IPF PPS was to include a patient classiﬁ cation system to reﬂ ect the differences in 
resource use and costs among IPFs, it was implemented without an associated assess-
ment tool. This project reviews Medicare PPSs in which diagnosis is not an adequate 
predictor of resource use; compares data collected via the related assessment instru-
ments, and discusses applicability to the IPF PPS. METHODS: The Medicare prospec-
tive payment systems were evaluated and the relevant systems isolated. The systems’ 
deﬁ ning criteria were deﬁ ned and the related assessment instruments explored for 
identifying measures. RESULTS: Under the current IPF PPS, Medicare pays for the 
per diem costs associated with furnishing covered inpatient psychiatric services via a 
nationally established base rate adjusted by geographic, facility and patient factors. 
Patient characteristics are limited to seventeen Medicare severity-diagnosis related 
groups (MS-DRGs), age, length of stay and certain co-morbidities but, unlike home 
health, skilled nursing and rehabilitation facility systems, do not account for functional 
status or other contributors to resource consumption. CONCLUSIONS: Patients in 
IPFs may vary in care needs despite common MS-DRG classiﬁ cation, thus require 
different resources. With limited ability to adjust beyond primary diagnosis, the 
current IPF PPS may misalign facility payment and expenses, ultimately impacting 
access to care. By analyzing other Medicare PPSs policy makers may positively con-
tribute to the reﬁ nement of this newest system.
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OBJECTIVES: The therapeutic reference price (RP) system in Germany is regarded as 
a successful mechanism to reduce pharmaceutical spending. However, later introduced 
price directed measures such as the so-called payer contracts (pharmaceutical tender 
contracts (TC) interact with the reference price mechanism. The aim of this paper is to 
compare and analyze the effects of both instruments on pharmaceutical price, volume 
and expenditure for substances at the period around loss of exclusivity. METHODS: a 
group of frequently prescribed drugs with patent expiry between the years of 2001 and 
2008 are investigated and the sales and unit data in the statutory health insurance system 
are analyzed for a period one year before and two year post patent expiry. RESULTS: 
The data show for the group with reference price and no tender contract (RP+/TC-) and 
with no reference price but tender contracts (RP-/TC+) similar level for the sales but 
signiﬁ cantly higher volume data for the ﬁ rst group. In the ﬁ rst year post patent expiry 
there seams to be a signiﬁ cant drop of sales and volume 9–12 month post patent expiry—
a period, when usually the reference price is set. The ﬁ gures for the groups with tender 
contracts (TC+) show a more steadily decline post patent expiry. The group RP+/TC+ 
is in terms of cost containment (sales decline) the most prominent one. If no regulation 
takes place, sales and volume increases even post patent expiry. CONCLUSIONS: Refer-
ence pricing and tender contracts are two cost containment measures, which are equally 
effective if applied alone, and which have additional impact, when applied together.
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OBJECTIVES: Considering the pharmaceutical expenditure trend and the current eco-
nomic and social context in Portugal, this study aims to: 1) analyze the national and 
international policy environments in Europe and US, concerning INN prescription and 
generic substitution, and 2) calculate the effect of generic substitution in Portugal, in terms 
of savings for the NHS and patients. METHODS: We conducted an international legisla-
tion review and generics market data. We estimated annual savings under the assumption 
of gradual increase in generics market share, and considering the difference between 
branded and generic medicines prices for each group of the Reference Price System (RPS). 
The database includes sales from Portuguese community pharmacies. RESULTS: The INN 
prescription is allowed in 20 countries of all 27 European countries and in all 50 US states. 
The generic substitution by pharmacists is allowed in 21 European countries (mandatory 
in 8) and in all US states (mandatory in 14). Despite the high increase from 2002, generics 
market share in Portugal is still below the European average, furthermore with a slowdown 
in its growth since 2005. The doctors prescribed 39.1% of drugs by brand name with no 
permission for substitution in 2009. The simulations generated savings of c120.4 million 
(50.8 for the NHS and c69.6 million for patients), less 11.1% of the medicines expenditure 
covered by the RPS. CONCLUSIONS: The market shares observed seem to reﬂ ect the 
different legislative frameworks. In Portugal, despite the growing share of generics, there 
is still a large potential market with signiﬁ cant opportunities of additional savings for the 
health system and patients, and may contribute to a higher pharmaceuticals accessibility 
as well to maximize therapeutic adherence.
PHP82
ASSESSMENT OF PHARMACEUTICAL EXPENDITURE TRENDS IN 
PORTUGAL—PRICING AND REIMBURSEMENT POLICY
Teixeira I, Mendes Z
CEFAR—Center for Health Evaluation Studies, Lisboa, Portugal
OBJECTIVES: The Stability and Growth Pact approved by the Portuguese Govern-
ment in 2010 limits the annual growth of public expenditure in 1% for drugs reim-
bursed in outpatient sector. Considering the 10.4% increased in pharmaceutical 
expenditure from the National Health Service (NHS) in the ﬁ rst 4 months of 2010, 
this study aims to identify the main factors of expenditure growth and implications 
of legislative modiﬁ cations in Portugal. METHODS: We have considered the policy 
changes concerning pricing and reimbursement and analyzed the database that 
includes sales from Portuguese community pharmacies and drugs prescription data. 
The statistical analysis of monthly data by product was performed with Statistical 
Analysis System (SAS), version 8.2. RESULTS: The new legislation approved in June 
2009, that establishes the generics reimbursement at 100% for pensioners whose 
income is below the national minimum wage was responsible for more c20.4 million 
of NHS spending in 2010. The special reimbursement regimes had also contributed 
positively for this trend: for example, the reimbursement rate raise for some anti-
asthmatics (from 37% to 69%) was responsible for c5.1 million (10.3%) of NHS 
expenditure increase. Nevertheless c10.7 million (21.5% of NHS expenditure growth) 
are explained by the top 10 branded drugs recently reimbursed (5 oral antidiabetics 
and 1 insulin). The reform in reimbursement system approved for July 2010 also 
predicts major changes in the expenditures trends. CONCLUSIONS: The legal frame-
work has a high impact in pharmaceuticals expenditures trends, and consequently in 
public ﬁ nancial burden and patient co-payments. The different policy measures 
adopted should be assessed on a periodic basis in order to monitor the market dynam-
ics and to identify the strategies that support the sustainable expenditure growth.
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OBJECTIVES: Due to the dynamic increase of pharmaceutical expenditure in the last 
decade different cost-containment method has been introduced by the European public 
insurance companies. The cost-effective drug reimbursement system might inﬂ uence 
the price level either in a direct or an indirect way, so the pricing strategy should be 
based on demand drivers and on factors of the regulatory environment as well. The 
goal of this analysis was to identify the effect the certain reimbursement solutions and 
local market characteristic on average price level of the predeﬁ ned submarket. 
METHODS: Before the statistical analysis we have built a comprehensive, standard-
ized and continuously updated international drug database based on ofﬁ cial sources 
which supported the analysis trough getting wider access to data’s. Because of the 
expected domestic introduce of international reference price system, we handled it 
with an extra attention among the explanatory variables. RESULTS: The variance of 
international pharmaceutical price level by the examined submarket found to be 
remarkable which can be explained by the difference product supply and the different 
apply of cost-containment methods of price regulation. CONCLUSIONS: The most 
effective way to curb the increased expenditure by the patient and the public insurance 
companies seems to be international reference price system; however the effect of this 
method differs across the countries.
PHP84
A PROPOSAL FOR CLASSIFICATION OF PUBLIC FUNDING 
RESTRICTIONS
Wilk NM
Arcana Institute, Krakow, Malopolskie, Poland
OBJECTIVES: Increasingly difﬁ cult situation of health care systems forces decision 
makers to limit access to publicly funded drugs compared to registration conditions. 
To keep the transparency, the decisions to deny health intervention to some group of 
patients have to be publicly justiﬁ ed—simple intuition is not enough. The objective is 
to present initial classiﬁ cation and details of methods to generate public funding 
restrictions. METHODS: A pool of public funding decisions has been identiﬁ ed 
through search of internet websites of the institutions that recommend or actually 
make public funding decisions. The speciﬁ c conditions restricting the access were 
identiﬁ ed, grouped and further analyzed together with their justiﬁ cation if available. 
RESULTS: All restrictions generally aim to optimize the performance of the decision 
